-
Suven Pharmaceuticals announces collaboration with Cipla for commercialization and distribution of Sustaneza Microspheres (Budesonide) Inhalation Aerosol in India
Suven Pharmaceuticals announces collaboration with Cipla for commercialization and distribution of Sustaneza Microspheres (Budesonide) Inhalation Aerosol in India
-
Suven Life Sciences gets US FDA approval for generic version of Albuterol Sulfate Inhalation Aerosol
Suven Life Sciences gets US FDA approval for generic version of Albuterol Sulfate Inhalation Aerosol
-
Suven Pharmaceuticals receives US FDA approval for generic version of Dexamethasone Sodium Phosphate Injection
Suven Pharmaceuticals receives US FDA approval for generic version of Dexamethasone Sodium Phosphate Injection
-
Suven Pharmaceuticals receives US FDA approval for generic version of Nystatin Oral Suspension
Suven Pharmaceuticals receives US FDA approval for generic version of Nystatin Oral Suspension
-
Suven Pharma gets US FDA nod for generic anti-depression drug
Suven Pharmaceuticals on Wednesday said its US-based arm has received approval from the US health regulator for generic Fluoxetine capsules used in the treatment of depression.
-
Suven Pharma launches generic Mometasone to treat eczema, psoriasis in US
Suven Pharmaceuticals on Tuesday said its US-based subsidiary has launched generic Mometasone Furoate Cream used for treating a range of skin conditions in the US market.
-
Suven Pharma arm gets USFDA nod for generic drug to treat acute lymphoblastic leukemia
Suven Pharmaceuticals on Wednesday said its wholly-owned subsidiary in the US has received approval from the US health regulator for generic Pegaspargase, used in the treatment of acute lymphoblastic leukemia.
-
Suven Life Sciences Granted US Patent for Novel Polymorphism of Dasatinib API
The United States Patent and Trademark Office (USPTO) has granted Suven Life Sciences a patent for a novel crystalline form of dasatinib API, a kinase inhibitor used to treat chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).
-
Suven Pharmaceuticals Receives US FDA Approval for Generic Version of Xeloda Tablets
Suven Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) to market its generic version of Xeloda tablets, a treatment for various types of cancer.
-
Suven Life Sciences Enters Collaboration with University of California, San Diego for Drug Discovery
Suven Life Sciences has announced a collaboration with the University of California, San Diego (UCSD) to discover and develop novel therapeutics for treating cancer and other diseases.
-
Suven Pharmaceuticals' US FDA ANDA Approved for Lithium Citrate Extended-Release Tablets, 450 mg
Suven Pharmaceuticals announced that it has received ANDA approval from the US FDA for its Lithium Citrate Extended-Release Tablets, 450 mg, which is therapeutically equivalent to Lithobid® Tablets, 450 mg of Endo Pharmaceuticals Inc.
-
Suven Pharmaceuticals Receives US FDA ANDA Approval for Ciprofloxacin Hydrochloride Injection, 200 mg/20 mL
Suven Pharmaceuticals announced that it has received ANDA approval from the US FDA for its Ciprofloxacin Hydrochloride Injection, 200 mg/20 mL, which is therapeutically equivalent to Cipro® I.V. Injection, 200 mg/20 mL of Bayer HealthCare Pharmaceuticals.
-
Suven Pharmaceuticals Announces Positive Phase 3 Clinical Trial Results for its Novel Drug Targeting Migraine, SUVN-G3033
Suven Pharmaceuticals announced positive results from its Phase 3 clinical trial evaluating the efficacy and safety of its novel drug, SUVN-G3033, in the acute treatment of migraine.
-
Suven Pharmaceuticals Receives US FDA ANDA Approval for Memantine Hydrochloride Extended-Release Capsules, 10 mg
Suven Pharmaceuticals announced that it has received ANDA approval from the US FDA for its Memantine Hydrochloride Extended-Release Capsules, 10 mg, which is therapeutically equivalent to Namenda® XR Capsules, 10 mg of AbbVie Inc.
-
Suven Pharmaceuticals receives from USFDA ANDA approval for Hydroxychloroquine Sulfate Tablets, 200 mg
Suven Pharmaceuticals Limited (Suven) announced that it has received ANDA approval from the US Food and Drug Administration (USFDA) for Hydroxychloroquine Sulfate Tablets, 200 mg. This is a generic version of Plaquenil Tablets, 200 mg, of Lupin Pharmaceuticals, Inc.
-
Suven Pharmaceuticals enters exclusive licensing and collaboration agreement with Nubiyota Inc. for development and commercialization of novel, oral, small molecule NLRP3 inflammasome inhibitors for multiple inflammatory diseases
Suven Pharmaceuticals Limited (Suven) announced today that it has entered into an exclusive licensing and collaboration agreement with Nubiyota, Inc. (Nubiyota), a clinical stage biopharmaceutical company focused on the development and commercialization of novel, oral, small molecule NLRP3 inflammasome inhibitors for the treatment of a wide range of inflammatory diseases.
-
Suven Pharmaceuticals receives tentative approval from USFDA for its Abbreviated New Drug Application (ANDA) of Lenalidomide Capsules 2.5mg, 5mg, 10mg, 15mg and 25mg
Suven Pharmaceuticals Limited (Suven) announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) of Lenalidomide Capsules 2.5mg, 5mg, 10mg, 15mg and 25mg.
-
Suven Pharma share price rises over 3% on healthy Q1 results
Suven Pharmaceuticals Limited's share price rose by over 3% on Monday after the company announced its financial results for the first quarter of the current fiscal year.
-
Suven Pharma gets USFDA approval for generic drug
Suven Pharmaceuticals Limited has received approval from the United States Food and Drug Administration (USFDA) for its generic drug product, levothyroxine sodium tablets.
-
Suven Pharma enters into licensing agreement with Dr. Reddy's
Suven Pharmaceuticals Limited has entered into a licensing agreement with Dr. Reddy's Laboratories Limited for the development and commercialization of a novel anti-infective drug.
